This inventor holds 59 USPTO granted patents and 1 published patent application, plus 3 CIPO patents and 4 EPO patents, primarily in Biochemical Modulators (CPC class C07D). Top assignees: Celltech Therapeutics Limited, Celltech R&d Limited, Ucbbiopharma Srl. Active years: 1992-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Inventors with similar research interests:
Location History:
- Stanmore, GB (1992 - 1994)
- Middlesex, GB (1999)
- Northwood, GB (1996 - 2005)
- Slough Berkshire, GB (2020)
- Slough, GB (2013 - 2023)
Company Filing History:
34 out of 81 
13 out of 68 
6 out of 129 
Years Active: 1992-2025
Areas of Expertise:
Title: The Innovative Contributions of Graham John Warrellow
Introduction: Graham John Warrellow, based in Northwood, GB, has made significant strides in the field of biopharmaceuticals, holding an impressive total of 58 patents. His innovative work has focused on the interactions of key proteins, particularly in the realm of disease treatment and prevention.
Latest Patents: Among his latest innovations are two pivotal patents. The first patent, titled “Method of identifying potential inhibitors of APO TNFα trimers,” describes a novel and stable trimeric structure of TNFα. This structure exhibits distorted symmetry, which allows it to bind effectively to the TNFR1 receptor, potentially improving treatments for diseases linked to the soluble TNFα/TNFR1 interaction. Importantly, this new TNFα configuration does not interfere with its signaling through TNFR2, thereby minimizing the risk of infections or malignancies in therapeutic applications.
The second patent, “Method for identifying a modulator of the TNFα or CD40L interaction with their cognate receptors,” reveals that certain compounds can stabilize a specific conformation of trimeric TNF that interacts with its receptor. This discovery opens the door for utilizing these compounds as modulators of TNF, and the patent also outlines a novel assay designed to identify further compounds with this mechanism of action.
Career Highlights: Graham has worked at renowned firms in the biopharmaceutical industry, including Celltech Therapeutics Limited and Celltech R&D Limited. His extensive background in these companies reflects his commitment to advancing medical science through innovative research and development.
Collaborations: Throughout his career, Graham has collaborated with esteemed colleagues, including John Clifford Head and John Robert Porter. Their combined expertise has contributed to the successful development and patenting of groundbreaking technologies in their field.
Conclusion: Graham John Warrellow's contributions to the biotechnology sector underscore the importance of innovation in developing new therapies. With 58 patents to his name, his work continues to pave the way for advancements in the treatment of diseases associated with critical protein interactions. His legacy is one of collaboration, creativity, and a deep commitment to enhancing healthcare outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile